
    
      â€¢ Assess the safety and efficacy of EMSAM (selegiline transdermal system) versus placebo in
      adolescents (aged 12 through 17 years) who meet criteria for Major Depressive Disorder (MDD)
      without psychotic features, single or recurrent
    
  